Competitive Salary: EMBL: EBPOD Fellowship: Single-cell Perturb-sequencing of Human NeuronsLocation:EMBL-EBI Hinxton, near Cambridge, UKContract Duration:3 years Closing Date:20 July 2018Position Details The European Bioinformatics Institute (EMBL-EBI), the NIHR Cambridge Biomedi Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: EBPOD Fellowship: Novel Computational Approaches to Improve Transplantation OutcomesLocation:EMBL-EBI Hinxton, near Cambridge, UKContract Duration:3 years Closing Date:20 July 2018Position Details The European Bioinformatics Institute (EMBL-EBI), the NIH Hinxton, Cambridgeshire, England

Applications MUST be submitted online and all applicants must submit a cover letter outlining qualifications and interests, along with a resume that includes...
From University of Wisconsin–Milwaukee - Thu, 24 May 2018 22:19:10 GMT - View all Milwaukee, WI jobs

Notice NOT-GM-18-034 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-802 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US. Specifically, the FOA solicits encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. These technologies should be practical and affordable in the low-resource settings, including remote or underserved populations within or outside the US. The technologies may include, but are not limited to tools for vaccine dissemination/delivery, imaging, in vitro diagnosis, or treatment of pre-cancerous (pre-neoplastic) or cancerous lesions that are preventable or treatable within low-resource settings. Strong emphasis is placed on technologies that directly provide or immediately lead to treatment options available in the local health system.

Funding Opportunity PAR-18-801 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US. Specifically, the FOA solicits encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. These technologies should be practical and affordable in the low-resource settings, including remote or underserved populations within or outside the US. The technologies may include, but are not limited to tools for vaccine dissemination/delivery, imaging, in vitro diagnosis, or treatment of pre-cancerous (pre-neoplastic) or cancerous lesions that are preventable or treatable within low-resource settings. Strong emphasis is placed on technologies that directly provide or immediately lead to treatment options available in the local health system.

Funding Opportunity PAR-18-798 from the NIH Guide for Grants and Contracts. The purpose of this grant program is to develop an understanding of the risks and conditions associated with occupational diseases and injuries, to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. NIOSH sponsors exploratory and developmental research projects by providing support for the early and conceptual stages of projects. Applicants must concisely describe the occupational health burden(s) being addressed in their proposal while also linking the need for the proposed research activities to planned outputs that will help address or alleviate this burden. Applicants should clearly articulate the anticipated impacts of the proposed research, both during the project period and beyond.

Funding Opportunity PAR-18-799 from the NIH Guide for Grants and Contracts. The purpose of the K01 grant program is to provide support and dedicated time for a supervised (mentored) career development experience in occupational safety and health research, leading to research independence. This grant program also is to help ensure the availability of adequate numbers of highly trained scientists and educators to address critical issues in occupational safety and health.

Funding Opportunity PAR-18-797 from the NIH Guide for Grants and Contracts. The purpose of this grant program is to develop an understanding of the risks and conditions associated with occupational diseases and injuries, to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. The NIOSH R03 grant mechanism supports small occupational safety and health research projects that can be carried out with limited resources such as pilot and feasibility studies, secondary data analysis or development of research methods.

Notice NOT-PM-18-003 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-800 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven research to discover human biomarkers in Parkinsons disease and other Parkinsonian syndromes, as a component of the NINDS Parkinsons Disease Biomarkers Program (PDBP). This FOA encourages biomarkers discovery projects in 1) genetically causal Parkinson's disease, especially for particular sub-types of Parkinson's Disease (PD), including genetic cohorts, biologically defined cohorts of idiopathic PD, or ethnic subgroups of idiopathic PD; 2) The differentiation of synucleinopathies (such as PD and Multiple System Atrophy (MSA) from tauopathies (such as Progressive Supranuclear Palsy and Corticobasal degeneration); or 3) to improve diagnostic differentiation between idiopathic/subtypes of PD and these disorders, as well as from Essential tremor. In order to further advance research in this area, broad sharing of biospecimens and associated data is a critical feature of the PDBP generally and of this FOA specifically. A timeline including milestones, which will be used to evaluate the application not only in peer review but also in consideration of the awarded project for funding of non-competing award years, is required for all studies.

Funding Opportunity RFA-RM-18-009 from the NIH Guide for Grants and Contracts. The NIH Director's Transformative Research Award supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Applications from individuals with diverse backgrounds and in any topic relevant to the broad mission of NIH are welcome. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to produce a major impact in a broad area of biomedical or behavioral research. The NIH Directors Transformative Research Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

Notice NOT-OD-18-186 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-070 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-184 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-18-008 from the NIH Guide for Grants and Contracts. The NIH Directors New Innovator Award supports early stage investigators of exceptional creativity who propose highly innovative new research approaches with the potential to produce a major impact on broad, important problems in biomedical or behavioral research. Applications from individuals with diverse backgrounds and in any topic relevant to the broad mission of NIH are welcome. The NIH Director's New Innovator Award complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The NIH Directors New Innovator Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

Funding Opportunity PAR-18-796 from the NIH Guide for Grants and Contracts. NLM wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.

Negotiable: Paramount Recruitment: Postdoctoral Scientist in Bioinformatics - 12 month contract Office Based in Berkshire - Office based - Informatics Team - Screening - Flow Cytometry Paramount are currently assisting an international pharmaceutical organisation with the exciting Berkshire, England

Notice NOT-HL-18-630 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Postdoctoral Scientist in Bioinformatics - 12 month contract Office Based in Berkshire - Office based - Informatics Team - Screening - Flow Cytometry Paramount are currently assisting an international pharmaceutical organisation with the exciting Berkshire, England